Importance of allogeneic stem cell transplantation in myelofibrosis
- Allogeneic stem cell transplantation (alloSCT) is the only curative treatment option for patients with high-risk myelofibrosis (MF). However, it is important to bear in mind that alloSCT in MF is associated with a nonrelapse mortality that should not be underestimated. Therefore, both exact disease risk categorization and thorough evaluation of the individual transplant-related risk are mandatory to identify those patients to whom alloSCT should be offered. This short review is intended to provide a concise overview on relevant aspects to be considered for patient selection, planning, and performing alloSCT.
Author: | Klaus HirschbühlORCiD, Christoph Schmid |
---|---|
URN: | urn:nbn:de:bvb:384-opus4-1158986 |
Frontdoor URL | https://opus.bibliothek.uni-augsburg.de/opus4/115898 |
ISSN: | 1865-5041OPAC |
ISSN: | 1865-5076OPAC |
Parent Title (English): | memo - Magazine of European Medical Oncology |
Publisher: | Springer |
Place of publication: | Berlin |
Type: | Article |
Language: | English |
Year of first Publication: | 2024 |
Publishing Institution: | Universität Augsburg |
Release Date: | 2024/10/17 |
Volume: | 17 |
Issue: | 3 |
First Page: | 215 |
Last Page: | 219 |
DOI: | https://doi.org/10.1007/s12254-024-00987-5 |
Institutes: | Medizinische Fakultät |
Medizinische Fakultät / Universitätsklinikum | |
Medizinische Fakultät / Lehrstuhl für Innere Medizin mit Schwerpunkt Hämatologie und Onkologie | |
Medizinische Fakultät / Professur für Transplantation und Zelltherapieforschung | |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Licence (German): | ![]() |